Clinical Trials in Egypt / NCT07853170
Recruiting
Not applicable
3-Needle vs 5-Needle of Genicular Nerve Block on Pain and Quality of Life in Knee Osteoarthritis
NCT07853170 · tracked via the Priya Life Science Egypt tracker
Condition(s) studied
3-Needle5-NeedleGenicular Nerve BlockPainQuality of LifeKnee Osteoarthritis
Investigational drug(s) / intervention(s)
3-nerve-targeted group5-nerve-targeted group
3-nerve-targeted group: Patients will receive 3-nerve protocol.
5-nerve-targeted group: Patients will receive 5-nerve protocol.
Study summary
This study aims to compare the 3-needle and 5-needle of genicular nerve block on pain and quality of life in Knee osteoarthritis (KOA).
Eligibility
Inclusion Criteria:
* Age ≥18 years.
* Both sexes.
* Patients with unilateral chronic knee pain for more than 3 months.
* Patients received conservative treatment for at least 3 months.
* Diagnosed Knee osteoarthritis (KOA) according to the American College of Rheumatology (ACR) criteria, and grade greater than or equal to Kellgren-Lawrence grade 2.
Exclusion Criteria:
* Chronic knee pain is due to causes other than KOA, such as connective tissue diseases, lumbar radicular neuropathy (spondylolisthesis, spinal stenosis), or sciatic pain.
* Knee effusion.
* Neuro/psychiatric disorders.
* History of intra-articular injection in the prior 3 months.
* Prior knee surgery.
* Active systemic or local knee infections; anticoagulant use.
Primary outcome measure(s)
- Degree of pain — 6 months postoperatively
Each patient will be instructed about postoperative pain assessment with the numeric rating scale (NRS) score. NRS (0 represents "no pain" while 10 represents "the worst pain imaginable").
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Tanta University | Tanta | El-Gharbia | Recruiting |
More Tanta University trials in Egypt
Other trials for the same condition
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07853170 on ClinicalTrials.gov ↗ ← All trials in Egypt